Adial Pharmaceuticals, Inc (ADIL) News
Filter ADIL News Items
ADIL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ADIL News Highlights
- For ADIL, its 30 day story count is now at 2.
- Over the past 21 days, the trend for ADIL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ADIL are DEC and NOV.
Latest ADIL News From Around the Web
Below are the latest news stories about ADIAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ADIL as an investment opportunity.
Adial Pharmaceuticals Receives Final Reimbursement Payment from AdovateCHARLOTTESVILLE, Va., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that on December 16, 2023, it received the final development cost reimbursement payment of $350,000 from Adovate, LLC under the terms of the final asset purchase agreement (the “FAA”) executed with Adovate |
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing RequirementCHARLOTTESVILLE, Va., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq today that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,00 |
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateAdvancing Discussions with Potential Strategic Partners Received Frost & Sullivan’s 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award Closed $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules; Extends Cash Runway into Q4 2024 CHARLOTTESVILLE, Va., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing thera |
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine ConferenceCHARLOTTESVILLE, Va., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the Chief Medical Officer of Adial, Bankole Johnson, D.Sc., M.D., and Key Opinion Leaders Jonathan Chick, M.D., Hannu Alho, M.D., and Icro Maremmani M.D., will be presenting at The Annual International |
All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to BuyAdial Pharmaceuticals, Inc. (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader WebinarExperts agree that there are benefits to reductions in drinking, supporting the ongoing development of non-abstinence-based therapies to treat alcohol use disorderCHARLOTTESVILLE, Va., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, recently hosted a virtual key opinion leader webinar with addictio |
Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesCHARLOTTESVILLE, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has closed its previously announced private placement offering for the purchase and sale of an aggregate of 1,418,440 shares of its common stock (or common stock equivalents in lieu thereof), series A warra |
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesCHARLOTTESVILLE, Va., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,418,440 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 1, |
EXCLUSIVE: Adial Pharma Announces Key Patent To Combine Genetic Diagnostic With Lead Drug For Alcohol AddictionAdial Pharmaceuticals Inc (NASDAQ: ADIL) has been awarded a key patent combining the use of the company's proprietary genetic diagnostic to detect select genotypes for genetically targeted treatment of alcohol use disorder (AUD) and opioid use disorder (OUD) with the company's lead investigational product AD04. AD04 is a genetically targeted, serotonin-3 receptor antagonist therapeutic agent for Alcohol Use Disorder in heavy drinking patients. "This patent marks another important milestone in ou |
Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25thCHARLOTTESVILLE, VA / ACCESSWIRE / October 19, 2023 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ... |